# An Early Access Program Guideline to Provide Access to Retifanlimab (INCMGA00012) Together With Carboplatin and Paclitaxel for Squamous Carcinoma of the Anal Canal (SCAC)

> **NCT06910137** · — · AVAILABLE · sponsor: **Incyte Corporation**

## Conditions studied

- Squamous Cell Carcinoma of the Anal Canal

## Interventions

- **DRUG:** retifanlimab

## Key facts

- **NCT ID:** NCT06910137
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06910137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06910137, "An Early Access Program Guideline to Provide Access to Retifanlimab (INCMGA00012) Together With Carboplatin and Paclitaxel for Squamous Carcinoma of the Anal Canal (SCAC)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06910137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*